Mississippi Was Among the First. Our Medical Cannabis Policy Should Lead.
Mississippi was among the first states where DEA officials began on-site implementation of the new federal framework for state-licensed medical cannabis—a distinction that reflects the strength of our program’s safeguards. Lawmakers should recognize that success while removing patient-access barriers that no longer fit the treatment of a Schedule III medicine.
By James Henry Crisler | Executive Director, Mississippi Medical Marijuana Association | August 2026
Federal inspectors came to Mississippi at the beginning of a historic transition and encountered licensed medical cannabis businesses already operating inside a strict, transparent system. That should inspire confidence—not another layer of stigma.
In June, federal Drug Enforcement Administration officials walked into two Mississippi medical cannabis dispensaries to begin on-site inspections connected to the new federal registration process. The operators were told they were among the first businesses in the country to receive those visits.[1]
That moment should matter to every Mississippi lawmaker. Federal officials did not begin this work in an untested market with no rules. They came to a state whose medical program already requires licensing, security, product testing, seed-to-sale tracking, detailed labels, inventory controls, practitioner certification, patient registration, and recurring inspections.
Mississippi is not standing at the edge of federal change. We are already helping define how that change will work.
The federal government changed the legal frame
In April 2026, the U.S. Department of Justice issued a final rule placing marijuana covered by a state medical-marijuana license in Schedule III of the Controlled Substances Act. The rule created an expedited DEA registration process for state licensees seeking to handle medical cannabis under federal law.[2]
This was not full legalization, and it did not turn every state-licensed product into an FDA-approved prescription drug. It is, however, the most consequential federal medical-cannabis policy change in our lifetimes: formal recognition of medical cannabis’ accepted medical use and lower potential for abuse than Schedule I and II substances. State licensure is now only one layer of compliance for Mississippi operators. Businesses entering the federal framework must also meet DEA registration, recordkeeping, security, inspection, and other federal requirements. That additional layer will likely increase compliance costs, and it raises the consequences of diversion, deficient records, or other illicit conduct by a license holder. The change is nevertheless transformative: state-licensed medical cannabis has moved out of the Schedule I framework that defined it as having no accepted medical use and into a category reserved for controlled substances with recognized medical use.
Schedule III is not an invitation to abandon standards. It is an instruction to use the right standards: medical standards, backed by evidence, accountability, and proportionate controls.
Mississippi earned its place at the front
Our program can withstand federal attention because Mississippi built it conservatively. Medical cannabis is cultivated, processed, tested, transported, and sold only by licensed businesses. Inventory is tracked from seed to sale. Products are subject to testing and labeling requirements. Dispensaries report transactions, regulators can audit the supply chain, and patients enter the program through authorized medical practitioners.
The results are measurable. Current MMCP dashboard figures show more than 70,000 active patients, 259 certifying practitioners, and 6,648 licensed workers. In calendar year 2025, the program recorded nearly $139 million in retail sales, approximately $2.18 million in cannabis excise-tax collections, and about $9 million in cannabis sales-tax revenue. The state’s annual report described expanding patient access, strong fiscal performance, increasing market maturity, and a program positioned for stability and long-term sustainability.[3]
Those figures represent more than an industry. They represent Mississippi patients who found relief through a program their state authorized, Mississippi workers finding valuable and rewarding positions in licensed facilities, and Mississippi businesses operating under rules that make every regulated sale visible.
The early DEA visits reinforce the point. Mississippi’s safeguards did more than qualify our operators to participate in the new federal framework. In practice, they put Mississippi near the front of the line as the DEA began translating federal policy into on-site oversight.
Strong regulation should protect access, not obstruct it
Lawmakers should preserve the controls that make the program credible: testing, accurate labels, secure facilities, inventory tracking, practitioner involvement, and meaningful enforcement. But strong regulation is not the same thing as maximum regulation. A rule is not successful merely because it is strict. It must also improve patient safety or program integrity.
Mississippi patients face layers of cannabis-specific requirements that are not ordinarily imposed on patients using other Schedule III medicines: a closed list of qualifying conditions, a separate state registry and identification card, mandatory certifications and follow-up requirements, special purchase allotments, and product-form or potency restrictions. Medical cannabis remains a distinct state-regulated pathway, not a conventional pharmacy prescription. But Schedule III recognition should force an honest review of whether each extra barrier is still justified.
The Legislature has already shown that this review is reasonable. In 2026, lawmakers passed House Bill 895 to eliminate the mandatory six-month follow-up visit, extend caregiver-card validity, and remove certain potency limits. Those reforms would not have dismantled testing, tracking, licensing, or enforcement. They targeted rules that restricted patients without strengthening the core safeguards that make the program work. Governor Tate Reeves vetoed the bill on March 26, leaving those reforms unenacted.[4]
That is the proper test for reform: keep rules that manage a demonstrated risk, revise rules that create cost and delay without a corresponding health benefit, and trust practitioners to make individualized decisions within a regulated system.
Do not confuse regulated medicine with intoxicating hemp
Mississippi’s medical program is often treated with greater suspicion than intoxicating hemp-derived products sold outside it. Psychoactive gummies, beverages, vapes, flower, and other products are available through smoke shops, convenience stores, specialty retailers, and online channels without a comparable statewide system of patient certification, practitioner oversight, seed-to-sale tracking, testing, sales reporting, or enforcement.
The Mississippi Board of Pharmacy has described intoxicating hemp products as loosely regulated, with inconsistent or absent testing, inaccurate or misleading labels, no clinical oversight, and risks from unknown potency, contaminants, adulterants, or synthetic cannabinoids. Its educational materials report that some products found in Mississippi contained as much as 5,000 milligrams of cannabinoids, including synthetic THCP.[5]
For two years, 3MA has also commissioned testing of intoxicating hemp products using Mississippi-licensed laboratories and the same analytical methods applied to regulated medical cannabis. That testing found products exceeding the federal THC threshold for hemp, products contaminated with heavy metals or pesticides, and labels that did not accurately describe what consumers were buying. These are not theoretical risks. They are products being offered in Mississippi’s ordinary retail market.
The contrast could not be clearer. A Mississippi medical cannabis product must move through licensed facilities, testing, tracking, labeling, and a registered patient’s interaction with a qualified practitioner. An intoxicating hemp product may reach a general consumer—including a young consumer—through a far less accountable channel. The federal government is recognizing the medical use of cannabis within a tightly regulated, state-licensed system. Mississippi lawmakers should recognize the other side of that lesson: intoxicating products produced and sold outside comparable safeguards should not receive easier access to the market than regulated medicine.
Let Mississippi lead with confidence
The federal shift gives Mississippi a choice. We can continue treating medical cannabis as a reluctant exception to prohibition, or we can recognize what our own program and the first round of federal inspections demonstrate: Mississippi has built a serious, accountable medical industry capable of operating under demanding oversight.
Recognition does not mean complacency. Lawmakers should continue strengthening testing, transparency, practitioner education, research, and coordination with federal regulators. For intoxicating hemp, the answer is not to invent a weaker parallel framework. Mississippi should apply the same core standards already required of medical cannabis—including licensing, in-state laboratory testing, seed-to-sale accountability, accurate labeling, secure distribution, and meaningful enforcement. Products that cannot meet those standards should be removed from convenience stores, smoke shops, and other general retail shelves and should not be sold in Mississippi.
At the same time, lawmakers should remove medical-cannabis restrictions that do not reflect the way other Schedule III medicines are governed and do not produce a measurable public-health benefit. Patients should not pay more, travel more, or wait longer simply because old stigma survived after the legal classification changed.
Mississippi was among the first places where the federal government began translating Schedule III policy into real-world oversight of state-licensed dispensaries. This move is evidence that our strict program has earned a place at the forefront of a national transformation.
Now our state policy should show the same confidence: preserve the safeguards that made Mississippi ready for federal oversight, remove unnecessary barriers for registered patients, apply those same safeguards to intoxicating hemp, and remove products that cannot comply from the marketplace. Mississippi helped lead the transition. Our lawmakers should act like it.
Sources
- Marijuana Moment, “DEA Begins On-Site Inspections at Marijuana Businesses That Applied for Federal Protections Under Trump’s Rescheduling Move,” June 18, 2026.
- U.S. Drug Enforcement Administration, Final Rule, “Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements.”
- Mississippi Medical Cannabis Program live data dashboard; Mississippi Medical Cannabis Program CY 2025 Annual Report.
- Mississippi Legislature, 2026 Summary of General Legislation, House Bill 895—vetoed March 26, 2026.
- Mississippi Board of Pharmacy, “Intoxicating Hemp-Derived Cannabinoids: What Healthcare Professionals Need to Know.”
Author’s note: This article expresses the author’s perspective and is intended for educational and policy-discussion purposes. It is not legal, tax, or medical advice.
Follow 3MA / Learn More
3mams.org | info@medicalmarijuanams.com
The Mississippi Medical Marijuana Association is a 501(c)(6) non-profit trade organization representing the interests of Mississippi’s medical cannabis community. 3MA works with operators, advocates, patients, policymakers, and regulators to support patient access, responsible industry growth, and meaningful improvements to Mississippi’s medical cannabis program.